A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases

Results at Up to 30 Years After Ileal Pouch–Anal Anastomosis for Chronic Ulcerative Colitis

(2017) Amy L. Lightner et al.   INFLAMMATORY BOWEL DISEASES

Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease

(2016) Clara Yzet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

(2016) Carina Götestam Skorpen et al.   ANNALS OF THE RHEUMATIC DISEASES

Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis

(2016) F. Gómez-García et al.   BRITISH JOURNAL OF DERMATOLOGY

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

(2016) Yanli Zhuang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis

(2016) Saakshi Khattri et al.   EXPERIMENTAL DERMATOLOGY

Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease

(2016) Bram Verstockt et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Safety of secukinumab in the treatment of psoriasis

(2016) Andrew Blauvelt   Expert Opinion On Drug Safety

Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature

(2016) X. Cortes et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Ustekinumab for Resistant Pediatric Crohn Disease

(2016) Firas Rinawi et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Ustekinumab in Pediatric Crohn Disease Patients

(2016) Casey Bishop et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Ustekinumab in Treatment of Refractory Paediatric Crohn Disease

(2016) F.L. Cameron et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

(2016) Peter C.M. van de Kerkhof et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis

(2016) Paweł Moćko et al.   Pharmacological Reports

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

(2015) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Pregnancy during Ustekinumab Treatment for Severe Psoriasis

(2015) Katiucia Rocha et al.   DERMATOLOGY

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

(2015) Ian Landells et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester

(2014) Claire Sheeran et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Not all monoclonals are created equal – Lessons from failed drug trials in Crohn's disease

(2014) Arthur Kaser   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients

(2014) Z.Z.N. Yiu et al.   BRITISH JOURNAL OF DERMATOLOGY

Demyelination in a patient receiving ustekinumab for refractory Crohn's disease: Figure 1

(2014) Yaeesh Badat et al.   Journal of Crohns & Colitis

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience

(2014) U. Kopylov et al.   Journal of Crohns & Colitis

Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis

(2014) A. Alsenaid et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

(2013) H.-Y. Chiu et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab for the treatment of Crohn’s disease

(2013) Reena Khanna et al.   Immunotherapy

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

How Cytokine Networks Fuel Inflammation: Interleukin-17 and a tale of two autoimmune diseases

(2013) Dominique L. P. Baeten et al.   NATURE MEDICINE

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

(2012) T.-F. Tsai et al.   BRITISH JOURNAL OF DERMATOLOGY

Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient

(2012) J. Koskinas et al.   BRITISH JOURNAL OF DERMATOLOGY

Seventeen in Crohn's disease: less prime than we thought?

(2012) Tim Raine et al.   GUT

Secukinumab failure in Crohn's disease: the yeast connection?

(2012) Jean Frédéric Colombel et al.   GUT

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings

(2012) David A. Martin et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

(2012) T. Tzellos et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reversible Posterior Leukoencephalopathy Syndrome in a Patient Treated With Ustekinumab

(2011) David Gratton   ARCHIVES OF DERMATOLOGY

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

(2011) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Molecular interactions within the IL-6/IL-12 cytokine/receptor superfamily

(2011) Lindsay L. Jones et al.   IMMUNOLOGIC RESEARCH

Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events

(2011) Caitriona Ryan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

(2011) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

(2011) Kenneth B. Gordon et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab

(2011) Jacqueline M Benson et al.   NATURE BIOTECHNOLOGY

Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

(2010) Pauline L. Martin et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I

(2010) Anne Puel et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines

(2010) Kai Kisand et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY